Schonfeld Strategic Advisors LLC Passage Bio, Inc. Transaction History

Schonfeld Strategic Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $11,448 - $15,984	-10,800 Reduced 51.92%	10,000 $13,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $37,554 - $76,339	-30,782 Reduced 59.68%	20,800 $26,000
Q2 2022 Aug 15, 2022	BUY	$1.63 - $3.46 $24,420 - $51,837	14,982 Added 40.93%	51,582 $122,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $97,356 - $237,534	36,600 New	36,600 $114,000
Q4 2020 Feb 16, 2021	SELL	$14.28 - $29.73 $261,324 - $544,059	-18,300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.39 - $26.15 $226,737 - $478,545	18,300 New	18,300 $0

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.